Reshape Lifesciences Inc (STU:24O0)
€ 0.615 0 (0%) Market Cap: 3.67 Mil Enterprise Value: 2.59 Mil PE Ratio: 0 PB Ratio: 1.07 GF Score: 38/100

ReShape Lifesciences Inc at Oppenheimer Fall Healthcare Life Sciences & MedTech Summit (Virtual) Transcript

Sep 20, 2021 / 06:05PM GMT
Release Date Price: €123.75 (+2.91%)
Shaymus Contorno
Oppenheimer & Co. - Analyst

Good afternoon. I am Shaymus Contorno from Oppenheimer's MedTech research team. Next up at our Fall Medtech Summit, we are pleased to welcome Barton Bandy, CEO; and Tom Stankovich, CFO, from ReShape Lifesciences.

With that, I'll turn it over to you, Bart and Tom.

Bart Bandy
ReShape Lifesciences Inc. - President and CEO

Great. Thank you, Shaymus. Welcome, everyone. It's our pleasure to present an update on ReShape Lifesciences. A lot has happened to our Company over the past few months. And we are really moving fast forward on some of the different projects that we've built out over the pandemic to make sure that we were ready, poised, and able to execute once we completed our merger with Obalon and brought in the funding necessary for our strategy and our execution. So as we go through that, we have our Safe Harbor statement and risk factors stated at the beginning of the presentation. I will give everybody a few seconds to review this.

And then we'll talk about it from an executive summary

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot